{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:36:32Z","timestamp":1790760992160,"version":"4.1.0"},"reference-count":59,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,11,7]]},"abstract":"<jats:p>In a review article, the authors discuss the present and future of molecular testing in chronic myeloid leukemia (CML) as a paradigm of the evolution of technologies assisting in better diagnosis, risk stratification, and response monitoring of leukemia and other cancers.<\/jats:p>","DOI":"10.1182\/blood.2019000838","type":"journal-article","created":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T23:25:12Z","timestamp":1568849112000},"page":"1578-1584","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":35,"title":["New approaches to molecular monitoring in CML (and other diseases)"],"prefix":"10.1182","volume":"134","author":[{"given":"Jerald","family":"Radich","sequence":"first","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and"},{"name":"Department of Pathology, University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Yeung","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and"},{"name":"Department of Pathology, University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Washington School of Medicine, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,9,18]]},"reference":[{"issue":"23","key":"2019111521054594100_B1","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"6","key":"2019111521054594100_B2","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia [published correction appears in Leukemia. 2010;24(5):1102]","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"issue":"9","key":"2019111521054594100_B3","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111521054594100_B4","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"issue":"24","key":"2019111521054594100_B5","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"19","key":"2019111521054594100_B6","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/blood-2012-02-410688","article-title":"A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"120","author":"Radich","year":"2012","journal-title":"Blood"},{"issue":"24","key":"2019111521054594100_B7","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111521054594100_B8","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111521054594100_B9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"19","key":"2019111521054594100_B10","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","article-title":"Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML","volume":"121","author":"Branford","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2019111521054594100_B11","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2019111521054594100_B12","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","article-title":"Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia","volume":"97","author":"Takahashi","year":"2012","journal-title":"Haematologica"},{"issue":"10","key":"2019111521054594100_B13","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"issue":"8","key":"2019111521054594100_B14","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.20922","article-title":"Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up","volume":"103","author":"Lahaye","year":"2005","journal-title":"Cancer"},{"issue":"8","key":"2019111521054594100_B15","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood-2011-10-383000","article-title":"Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients","volume":"119","author":"Milojkovic","year":"2012","journal-title":"Blood"},{"issue":"19","key":"2019111521054594100_B16","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"2019111521054594100_B17","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"issue":"7","key":"2019111521054594100_B18","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4065\/81.7.973","article-title":"Chronic myeloid leukemia: diagnosis and treatment","volume":"81","author":"Quint\u00e1s-Cardama","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"2019111521054594100_B19","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1182\/blood-2009-02-204693","article-title":"Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance","volume":"114","author":"Verma","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2019111521054594100_B20","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1586\/14737159.2013.835573","article-title":"BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring","volume":"13","author":"Luu","year":"2013","journal-title":"Expert Rev Mol Diagn"},{"issue":"24","key":"2019111521054594100_B21","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2019111521054594100_B22","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2004-03-1134","article-title":"Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations","volume":"104","author":"Branford","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2019111521054594100_B23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1373\/clinchem.2014.221366","article-title":"Considerations for digital PCR as an accurate molecular diagnostic tool","volume":"61","author":"Huggett","year":"2015","journal-title":"Clin Chem"},{"issue":"5","key":"2019111521054594100_B24","doi-asserted-by":"crossref","first-page":"896","DOI":"10.3109\/10428194.2011.555569","article-title":"Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay","volume":"52","author":"Goh","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2019111521054594100_B25","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jmoldx.2013.10.007","article-title":"Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR","volume":"16","author":"Jennings","year":"2014","journal-title":"J Mol Diagn"},{"issue":"2","key":"2019111521054594100_B26","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/leu.2008.183","article-title":"Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR","volume":"23","author":"Oehler","year":"2009","journal-title":"Leukemia"},{"issue":"12","key":"2019111521054594100_B27","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.3324\/haematol.2018.189787","article-title":"BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia","volume":"103","author":"Pagani","year":"2018","journal-title":"Haematologica"},{"issue":"26","key":"2019111521054594100_B28","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"issue":"17","key":"2019111521054594100_B29","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1158\/1078-0432.CCR-13-3231","article-title":"Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH","volume":"20","author":"Wu","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"134","key":"2019111521054594100_B30","doi-asserted-by":"crossref","first-page":"134ra63","DOI":"10.1126\/scitranslmed.3003656","article-title":"High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia","volume":"4","author":"Wu","year":"2012","journal-title":"Sci Transl Med"},{"key":"2019111521054594100_B31","first-page":"61","article-title":"The weirdest people in the world?","volume-title":"Behav Brain Sci","author":"Henrich","year":"2010"},{"issue":"9","key":"2019111521054594100_B32","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1373\/clinchem.2007.085472","article-title":"Development of an integrated assay for detection of BCR-ABL RNA","volume":"53","author":"Winn-Deen","year":"2007","journal-title":"Clin Chem"},{"issue":"s1 Suppl 1","key":"2019111521054594100_B33","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1086\/650392","article-title":"Quantifying HIV for monitoring antiretroviral therapy in resource-poor settings","volume":"201","author":"Stevens","year":"2010","journal-title":"J Infect Dis"},{"issue":"13","key":"2019111521054594100_B34","first-page":"1719","article-title":"Detection and direct sequence identification of BCR-ABL mRNA in Ph+ chronic myeloid leukemia","volume":"21","author":"Sooknanan","year":"1993","journal-title":"Exp Hematol"},{"issue":"4","key":"2019111521054594100_B35","first-page":"262","article-title":"Development of reverse transcription loop-mediated isothermal amplification for simple and rapid detection of promyelocytic leukemia-retinoic acid receptor \u03b1 mRNA","volume":"59","author":"Hashimoto","year":"2016","journal-title":"Yonago Acta Med"},{"issue":"22","key":"2019111521054594100_B36","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2015-12-689059","article-title":"Paper or plastic? BCR-ABL1 quantitation and mutation detection from dried blood spots","volume":"127","author":"Sala Torra","year":"2016","journal-title":"Blood"},{"issue":"15","key":"2019111521054594100_B37","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/blood-2009-03-212969","article-title":"The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data","volume":"114","author":"Oehler","year":"2009","journal-title":"Blood"},{"issue":"8","key":"2019111521054594100_B38","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1073\/pnas.0510423103","article-title":"Gene expression changes associated with progression and response in chronic myeloid leukemia","volume":"103","author":"Radich","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"2019111521054594100_B39","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00432-014-1845-6","article-title":"Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase","volume":"141","author":"Machova Polakova","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"issue":"16","key":"2019111521054594100_B40","doi-asserted-by":"crossref","first-page":"21982","DOI":"10.18632\/oncotarget.8010","article-title":"Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients","volume":"7","author":"Soverini","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"2019111521054594100_B41","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1186\/1471-2105-12-451","article-title":"Identification and correction of systematic error in high-throughput sequence data","volume":"12","author":"Meacham","year":"2011","journal-title":"BMC Bioinformatics"},{"issue":"5","key":"2019111521054594100_B42","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrg.2017.117","article-title":"Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations","volume":"19","author":"Salk","year":"2018","journal-title":"Nat Rev Genet"},{"issue":"11","key":"2019111521054594100_B43","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/nprot.2014.170","article-title":"Detecting ultralow-frequency mutations by duplex sequencing [published correction appears in Nat Protoc. 2014;9(12):2903]","volume":"9","author":"Kennedy","year":"2014","journal-title":"Nat Protoc"},{"issue":"36","key":"2019111521054594100_B44","doi-asserted-by":"crossref","first-page":"14508","DOI":"10.1073\/pnas.1208715109","article-title":"Detection of ultra-rare mutations by next-generation sequencing","volume":"109","author":"Schmitt","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5910","key":"2019111521054594100_B45","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1126\/science.1162986","article-title":"Real-time DNA sequencing from single polymerase molecules","volume":"323","author":"Eid","year":"2009","journal-title":"Science"},{"issue":"4","key":"2019111521054594100_B46","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1073\/pnas.0710982105","article-title":"Selective aluminum passivation for targeted immobilization of single DNA polymerase molecules in zero-mode waveguide nanostructures","volume":"105","author":"Korlach","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2019111521054594100_B47","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/1755-0998.12324","article-title":"A first look at the Oxford Nanopore MinION sequencer","volume":"14","author":"Mikheyev","year":"2014","journal-title":"Mol Ecol Resour"},{"issue":"9","key":"2019111521054594100_B48","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"issue":"5","key":"2019111521054594100_B49","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/ijlh.12394","article-title":"Reconsideration of BCR-ABL protein flow cytometric immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia?","volume":"37","author":"Kelani","year":"2015","journal-title":"Int J Lab Hematol"},{"issue":"1","key":"2019111521054594100_B50","doi-asserted-by":"crossref","first-page":"14049","DOI":"10.1038\/ncomms14049","article-title":"Massively parallel digital transcriptional profiling of single cells","volume":"8","author":"Zheng","year":"2017","journal-title":"Nat Commun"},{"issue":"17","key":"2019111521054594100_B51","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1182\/blood-2016-07-728873","article-title":"Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML","volume":"129","author":"Warfvinge","year":"2017","journal-title":"Blood"},{"issue":"281","key":"2019111521054594100_B52","doi-asserted-by":"crossref","first-page":"281re2","DOI":"10.1126\/scitranslmed.aaa0763","article-title":"Single-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia","volume":"7","author":"Paguirigan","year":"2015","journal-title":"Sci Transl Med"},{"issue":"12","key":"2019111521054594100_B53","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111521054594100_B54","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"issue":"8","key":"2019111521054594100_B55","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.2015.9643","article-title":"Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia","volume":"314","author":"Klco","year":"2015","journal-title":"JAMA"},{"issue":"11","key":"2019111521054594100_B56","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMc1500684","article-title":"Clonal hematopoiesis and blood-cancer risk","volume":"372","author":"Genovese","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"2019111521054594100_B57","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"issue":"132","key":"2019111521054594100_B58","doi-asserted-by":"crossref","first-page":"132ra54","DOI":"10.1126\/scitranslmed.3003787","article-title":"Vascular COX-2 modulates blood pressure and thrombosis in mice","volume":"4","author":"Yu","year":"2012","journal-title":"Sci Transl Med"},{"issue":"5","key":"2019111521054594100_bib59","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nmeth.3351","article-title":"Sequencing of small genomic targets with high efficiency and extreme accuracy","volume":"12","author":"Schmitt","year":"2015","journal-title":"Nat Methods"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/19\/1578\/1505327\/bloodbld2019000838c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/134\/19\/1578\/1505327\/bloodbld2019000838c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T04:43:31Z","timestamp":1573879411000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/134\/19\/1578\/374986\/New-approaches-to-molecular-monitoring-in-CML-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,18]]},"references-count":59,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2019,9,18]]},"published-print":{"date-parts":[[2019,11,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2019000838","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,18]]}}}